华厦眼科
(301267)
| 流通市值：96.62亿 | | | 总市值：125.16亿 |
| 流通股本：6.48亿 | | | 总股本：8.40亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,341,348,589.86 | 2,185,227,265.04 | 1,150,088,313.1 | 4,139,163,024.64 |
| 营业收入 | 3,341,348,589.86 | 2,185,227,265.04 | 1,150,088,313.1 | 4,139,163,024.64 |
| 二、营业总成本 | 2,755,345,546.6 | 1,819,478,008.53 | 926,648,751.89 | 3,566,671,659.42 |
| 营业成本 | 1,850,982,739.28 | 1,221,175,551.04 | 619,529,905.42 | 2,346,559,577.4 |
| 税金及附加 | 12,768,327.46 | 9,288,645.6 | 4,594,679.27 | 16,999,095.61 |
| 销售费用 | 434,231,250.88 | 286,915,614.62 | 149,482,705.05 | 572,723,556.82 |
| 管理费用 | 376,626,229.61 | 247,432,284.54 | 125,459,378.6 | 521,469,213.53 |
| 研发费用 | 43,745,643.25 | 29,932,941.48 | 15,237,765.04 | 61,437,372.83 |
| 财务费用 | 36,991,356.12 | 24,732,971.25 | 12,344,318.51 | 47,482,843.23 |
| 其中:利息费用 | 33,606,415.44 | 22,633,833.9 | 11,425,420.66 | 46,957,949.79 |
| 其中:利息收入 | 1,483,665.9 | 1,074,708.31 | 768,114.59 | 5,620,176.01 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 25,677,952.32 | 24,080,187.82 | 10,292,906.88 | -9,293,793.21 |
| 加:投资收益 | 10,317,176.81 | -2,857,898.06 | -1,984,796.59 | 46,597,434.87 |
| 资产处置收益 | 5,868,804.47 | 5,789,983.22 | 5,009,235.33 | 2,455,566.4 |
| 资产减值损失(新) | -1,031,704.84 | -1,101,693.43 | 1,952.82 | -7,821,730.39 |
| 信用减值损失(新) | -4,649,436.19 | -2,228,594.6 | -3,292,939.88 | -6,823,968.57 |
| 其他收益 | 22,543,547.39 | 9,761,896.28 | 8,773,407.68 | 17,990,252.05 |
| 四、营业利润 | 644,729,383.22 | 399,193,137.74 | 242,239,327.45 | 615,595,126.37 |
| 加:营业外收入 | 8,049,270.92 | 3,753,909.84 | 799,834.02 | 4,490,668.17 |
| 减:营业外支出 | 17,272,525.07 | 11,840,816.14 | 7,569,751.96 | 46,273,466.95 |
| 五、利润总额 | 635,506,129.07 | 391,106,231.44 | 235,469,409.51 | 573,812,327.59 |
| 减:所得税费用 | 142,033,245.25 | 87,665,079.09 | 51,216,561.09 | 140,756,058.83 |
| 六、净利润 | 493,472,883.82 | 303,441,152.35 | 184,252,848.42 | 433,056,268.76 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 493,472,883.82 | 303,441,152.35 | 184,252,848.42 | 433,056,268.76 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 466,143,950.36 | 291,961,802.7 | 171,662,280.94 | 440,654,460.97 |
| 少数股东损益 | 27,328,933.46 | 11,479,349.65 | 12,590,567.48 | -7,598,192.21 |
| 扣除非经常损益后的净利润 | 407,667,493.89 | 260,960,250.69 | 153,950,095.18 | 425,416,771.81 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.55 | 0.35 | 0.2 | 0.53 |
| (二)稀释每股收益 | 0.55 | 0.35 | 0.2 | 0.53 |
| 八、其他综合收益 | -791,101.17 | -502,240.63 | -266,313.61 | -1,029,332.98 |
| 归属于母公司股东的其他综合收益 | -791,101.17 | -502,240.63 | -266,313.61 | -1,029,332.98 |
| 九、综合收益总额 | 492,681,782.65 | 302,938,911.72 | 183,986,534.81 | 432,026,935.78 |
| 归属于母公司股东的综合收益总额 | 465,352,849.19 | 291,459,562.07 | 171,395,967.33 | 439,625,127.99 |
| 归属于少数股东的综合收益总额 | 27,328,933.46 | 11,479,349.65 | 12,590,567.48 | -7,598,192.21 |
| 公告日期 | 2026-10-27 | 2026-08-28 | 2026-04-28 | 2026-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |